Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Pacific Biosciences of California to post earnings of ($0.26) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last released its earnings results on Thursday, February 15th. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.02. Pacific Biosciences of California had a negative return on equity of 40.23% and a negative net margin of 152.97%. The company had revenue of $58.36 million during the quarter, compared to analysts’ expectations of $57.96 million. During the same period in the prior year, the business posted ($0.35) EPS. The business’s revenue was up 113.3% on a year-over-year basis. On average, analysts expect Pacific Biosciences of California to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Pacific Biosciences of California Stock Performance
Shares of PACB opened at $1.69 on Thursday. The business’s fifty day moving average price is $3.51 and its 200 day moving average price is $6.25. Pacific Biosciences of California has a 12-month low of $1.25 and a 12-month high of $14.55. The stock has a market capitalization of $452.84 million, a PE ratio of -1.40 and a beta of 1.83. The company has a debt-to-equity ratio of 1.27, a current ratio of 7.81 and a quick ratio of 7.21.
Insider Buying and Selling at Pacific Biosciences of California
Analyst Upgrades and Downgrades
PACB has been the topic of several analyst reports. Scotiabank dropped their target price on Pacific Biosciences of California from $15.00 to $8.00 and set a “sector outperform” rating on the stock in a research report on Thursday, April 18th. TD Cowen lowered their price target on Pacific Biosciences of California from $12.00 to $2.50 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Sanford C. Bernstein lowered their price target on Pacific Biosciences of California from $9.00 to $2.50 and set an “outperform” rating on the stock in a report on Thursday, April 18th. JPMorgan Chase & Co. lowered Pacific Biosciences of California from an “overweight” rating to a “neutral” rating in a report on Monday, April 22nd. Finally, UBS Group lowered their price target on Pacific Biosciences of California from $12.50 to $12.00 and set a “buy” rating on the stock in a report on Friday, February 16th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.77.
Read Our Latest Report on Pacific Biosciences of California
About Pacific Biosciences of California
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
See Also
- Five stocks we like better than Pacific Biosciences of California
- How to buy stock: A step-by-step guide for beginners
- AMD is Down 35%. Now is the Time to Buy the Dip
- Investing in Commodities: What Are They? How to Invest in Them
- Amazon Stands Tall: New Highs Are in Sight
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.